HALO (STOCKS)
Halozyme Therapeutics, Inc.
$100.670000
-1.120000 (-1.10%)
Prev close: $101.790000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Helen I. Torley
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $14,134.02M
- Employees
- 350
- P/E (TTM)
- 30.41
- P/B (TTM)
- 80.87
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $1.66B |
| Benefits Costs and Expenses | $1.08B |
| Cost Of Revenue | $292.42M |
| Costs And Expenses | $1.07B |
| Gross Profit | $1.37B |
| Operating Expenses | $774.12M |
| Selling, General, and Administrative Expenses | $238.00M |
| Other Operating Expenses | $515.24M |
| Operating Income/Loss | $597.20M |
| Income/Loss From Continuing Operations After Tax | $413.60M |
| Income/Loss From Continuing Operations Before Tax | $583.34M |
| Income Tax Expense/Benefit | $169.74M |
| Net Income/Loss | $413.60M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $413.60M |
| Net Income/Loss Available To Common Stockholders, Basic | $413.60M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $3.56 |
| Diluted Earnings Per Share | $3.43 |
| Basic Average Shares | 351,907,000 |
| Diluted Average Shares | 365,876,000 |
| Assets | $2.58B |
| Current Assets | $933.02M |
| Inventory | $137.14M |
| Other Current Assets | $795.89M |
| Noncurrent Assets | $1.64B |
| Fixed Assets | $49.76M |
| Intangible Assets | $922.44M |
| Other Non-current Assets | $672.18M |
| Liabilities | $2.43B |
| Current Liabilities | $344.44M |
| Accounts Payable | $23.61M |
| Other Current Liabilities | $320.83M |
| Noncurrent Liabilities | $2.09B |
| Equity | $143.54M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $143.54M |
| Liabilities And Equity | $2.58B |
| Net Cash Flow From Operating Activities | $818.60M |
| Net Cash Flow From Operating Activities, Continuing | $818.60M |
| Net Cash Flow From Investing Activities | -$605.72M |
| Net Cash Flow From Investing Activities, Continuing | -$605.72M |
| Net Cash Flow From Financing Activities | -$110.75M |
| Net Cash Flow From Financing Activities, Continuing | -$110.75M |
| Net Cash Flow | $102.13M |
| Net Cash Flow, Continuing | $102.13M |
| Comprehensive Income/Loss | $434.17M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $434.17M |
| Other Comprehensive Income/Loss | $434.17M |